OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of OncoCyte (NASDAQ:OCX) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $4.25 price objective on the stock.

Separately, StockNews.com started coverage on OncoCyte in a report on Friday, November 8th. They set a “sell” rating for the company.

OncoCyte Stock Performance

NASDAQ OCX opened at $2.94 on Wednesday. OncoCyte has a 52 week low of $2.29 and a 52 week high of $4.34. The business has a 50 day moving average price of $3.04 and a 200-day moving average price of $2.98.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The firm had revenue of $0.12 million for the quarter. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 237.81%. During the same period last year, the company posted ($0.57) EPS.

Insider Activity at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the transaction, the insider now directly owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Andrea S. James bought 33,670 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average price of $2.97 per share, with a total value of $99,999.90. Following the completion of the transaction, the chief financial officer now directly owns 33,670 shares in the company, valued at approximately $99,999.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the transaction, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.58% of the stock is owned by insiders.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.